Document is current
Any future updates will be listed below
-
Authors
Hopp, Thomas P. https://orcid.org/0000-0001-5552-7190
Matthews, Maura-Ann H.
Spiewak, Klaudyna
Athanasiou, Zafeiria
Blackmore, Richard S.
Gelbfish, Gary A.
-
Funding
Funding for this research was provided by:
Victoria Medical Research Acceleration Fund, DHHS Victoria, Australia
- License Information
-
More Information
Article History
Received: 30 July 2022
Accepted: 17 December 2022
First Online: 29 December 2022
Declarations
:
: All authors have no competing interests to declare.
: The trial in which the clinical specimens were collected had approval from the Human Research and Ethics Committee of the Alfred Hospital, Melbourne, Australia (Project number 493/18). All participants gave written informed consent. In compliance with Australian regulations, Metrodora Therapeutics, the sponsor, notified Australia’s Therapeutic Goods Administration (TGA) via the Clinical Trial Notification scheme (CTN; clinical trial: CT-2018-CTN-03362-1) and registered with the Australian New Zealand Clinical Trials Registry (ANZCTR; ACTRN12619000295145) prior to starting the trial.
